Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Provided By GlobeNewswire
Last update: Jan 27, 2025
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® -
Read more at globenewswire.comNASDAQ:DRTSW (10/30/2025, 8:03:52 PM)
0.3199
-0.04 (-11.14%)
NASDAQ:DRTS (10/31/2025, 8:00:01 PM)
4.165
+0.13 (+3.09%)
Find more stocks in the Stock Screener
